Dupilumab Improves Health-Related Quality of Life (HRQoL) and Reduces Symptom Burden in Patients with Eosinophilic Esophagitis (EoE): Results From Part A of a Randomized, Placebo-Controlled Three-Part Phase 3 Study - 01/02/21
Doi : 10.1016/j.jaci.2020.12.347
Evan Dellon, MD 1, Marc Rothenberg, MD PhD FAAAAI 2, Ikuo Hirano, MD 3, Mirna Chehade, MD MPH 4, Albert J. Bredenoord 5, Jonathan Spergel, MD, PhD 6, Qiong Zhao 7, Bethany Beazley 7, Isabelle Guillemin 8, Leda Mannent, MD 8, Elizabeth Laws 8, Nikhil Amin, MD 7, Brad Shumel, MD 7, Jennifer Maloney 7, Siddhesh Kamat 7
1 University of North Carolina School of Medicine
2 Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine
3 Northwestern University Feinberg School of Medicine
4 Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai
5 Amsterdam University Medical Center
6 Children's Hospital of Philadelphia
7 Regeneron Pharmaceuticals, Inc.
8 Sanofi
290
Il testo completo di questo articolo è disponibile in PDF.Mappa
© 2020
Pubblicato da Elsevier Masson SAS.
Vol 147 - N° 2S
P. AB91 - Febbraio 2021 Ritorno al numero
Articolo precedente
- Increased Prevalence of Eosinophilic Esophagitis (EoE) in Children with Inflammatory Bowel Disease (IBD)
- Ryan Eid, Christina Mounzer, Michael Mendoza, Jeremy Middleton, Barrett Barnes, Emily McGowan
- Efficacy And Safety Of Budesonide Oral Suspension In A Pediatric Population: Pooled Data From A Phase 2 And Phase 3 Trial In Patients With Eosinophilic Esophagitis
- Sandeep Gupta, Vincent Mukkada, Evan Dellon, Benjamin Gold, Margaret Collins, David Katzka, Gary Falk, Lan. Lan, Nirav Desai, James Williams, Ikuo Hirano
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?